U.S. IT Stock News

Arthur J. Gallagher & Co. recently filed a Form 8-K under Regulation FD and, earlier this month, held an investor meeting that shared updated 2025–2026 estimates and details on net after-tax cash flows from its clean energy investments. At the same time, several research firms, including Evercore ISI and Truist, reassessed their views on the company in light of softer organic growth expectations and property pricing pressures, prompting investors to reconsider how much growth risk is already...

BKV Corporation recently announced that its Board of Directors has authorized a two-year share repurchase program of up to US$100 million of its outstanding common stock, to be funded through available cash or borrowings under its existing reserve-based lending agreement. The buyback authorization, coming shortly after a public offering that raised about US$170.3 million linked to a planned power asset acquisition, highlights how BKV is actively reshaping its capital structure and capital...

Vertex Pharmaceuticals recently reported new clinical data showing that all evaluable children aged 5–11 treated with CASGEVY achieved key endpoints in sickle cell disease and transfusion-dependent beta thalassemia, and also secured an FDA National Priority Voucher to accelerate review in this younger age group. By pairing strong pediatric efficacy signals with an expedited U.S. regulatory review pathway, Vertex is strengthening CASGEVY’s potential role in reshaping treatment for severe...

Insight Enterprises recently amended its asset-based credit agreement, lifting its revolving credit facility to the US$2.00 billions equivalent, extending its maturity to December 19, 2030, and adding more flexibility around receivables sales across multiple geographies and currencies. On the same day, the company also completed a prior repurchase plan and authorized a new US$299 million share buyback, signaling management’s confidence in liquidity and capital allocation discipline. Next,...

Immunovant (IMVT) just raised roughly $550 million through a follow on equity offering at $21 a share, a meaningful capital boost that also brings the usual dilution questions front and center for investors. See our latest analysis for Immunovant. The offering lands on top of a strong run, with a 30 day share price return of about 15 percent and a 90 day surge of more than 80 percent. The three year total shareholder return above 60 percent suggests longer term momentum has been building...

For investors wondering whether Guardant Health is still a smart buy after its massive run up, or if new investors might be late to the party, this article will walk through what the current price is really baking in. The stock has surged an eye catching 214.9% over the last year and 213.9% year to date, even if the last week and month have been relatively flat at -2.3% and 0.2% respectively. Behind those moves, investors have been reacting to a steady drumbeat of news around Guardant's...

CNX Resources recently completed a privately negotiated exchange of about US$122.1 million of its 2.25% Convertible Senior Notes due 2026 for approximately US$0.8 million in cash and 9,509,188 new common shares, while also announcing a CFO transition effective January 1, 2026. This balance-sheet reshaping and leadership change could influence how investors assess CNX Resources’ leverage, equity base, and ability to execute its long-term plan. We’ll now examine how this sizable...

In recent months, institutional investors including Riverwater Partners and ARK Invest have reduced or exited positions in Iridium Communications, citing slowing growth, rising leverage, and tougher competitive conditions in some end markets. These moves highlight how quickly sentiment can shift when a company perceived as a long-term satellite connectivity leader begins to show softer growth expectations and a higher risk profile. We’ll now examine how institutional selling tied to concerns...

In recent days, Vishay Intertechnology announced the launch of two thin film chip fuse series (S2F and S3F) and a new AEC-Q200-qualified 0402 glass-protected NTC thermistor, expanding its portfolio of circuit protection and precision temperature sensing components. These compact, high-reliability parts, spanning fast and very fast fusing options and high-precision thermistors for automotive and industrial uses, underline Vishay’s push to deepen its presence in critical electronic...

Earlier in 2025, Fiserv cut its full-year revenue forecast after weaker-than-expected results and slowing growth in its Clover merchant-services segment, while also facing a securities class action tied to its guidance reset and operational execution. At the same time, several high-profile asset managers increased their holdings and Fiserv accelerated share buybacks, underscoring a divide between skeptical analysts and investors who see long-term value in the company’s payments and fintech...

WESCO International recently announced that its Board unanimously approved the appointment of two new independent directors, Michael L. Carter and David C. Wajsgras, effective January 1, 2026, while longstanding directors Bobby Griffin and Steven Raymund plan to retire at the 2026 annual meeting. The addition of leaders with deep banking, aerospace, defense, and infrastructure experience could influence how WESCO thinks about capital markets access and long-term growth opportunities. Next,...

In recent days, analysts at firms including Goldman Sachs and Needham reiterated positive views on Viridian Therapeutics after the company submitted a Biologics License Application to the FDA for its lead thyroid eye disease therapy, veli. These endorsements highlight how Viridian’s plan to convert existing Tepezza prescribers and potentially broaden veli’s label with Phase 3 data could reshape expectations for its rare disease portfolio. With FDA review of veli’s application now underway,...

Amneal Pharmaceuticals (AMRX) just secured FDA approval for its 1 mg/mL epinephrine injection in single and multi dose vials, plugging into a critical hospital therapy market with roughly $118 million in U.S. annual sales. See our latest analysis for Amneal Pharmaceuticals. The FDA approval lands as Amneal’s share price sits at $12.57 and recent momentum has been strong, with a roughly 62 percent year to date share price return and a powerful multi year total shareholder return backing the...

Digi International (DGII) has quietly outperformed the broader market this year, with the stock up roughly 50% year to date and about 17% over the past 3 months, drawing fresh attention to its IoT-focused business model. See our latest analysis for Digi International. That kind of run, capped by a recent 1 month share price return of just over 10 percent and a current share price around 43 dollars and 86 cents, suggests momentum is still building as investors warm to Digi International's IoT...

AGNC Investment Corp. recently expanded its board from eight to nine members and appointed former Voya Investment Management CEO Christine L. Hurtsellers, CFA, to serve as an independent director and Audit Committee member, while also declaring its regular monthly common dividend of US$0.12 per share for December 2025 and fourth-quarter preferred dividends. By adding a mortgage-backed securities veteran with extensive risk management experience and affirming both common and preferred...

Planet Labs PBC recently reported third-quarter 2025 results showing revenue of US$81.25 million versus US$61.27 million a year earlier, alongside a wider net loss of US$59.19 million, and issued guidance for fourth-quarter and full-year 2026 revenue of US$76–80 million and US$297–301 million respectively. Ahead of these financial updates, Planet Labs also released first light images from its new Pelican-6 high-resolution satellite, highlighting ongoing advances in its Earth observation...

In the past week, NetScout Systems reported second quarter fiscal 2026 results with both earnings per share and revenue coming in well above analyst expectations, while director Christopher Perretta sold 10,000 shares under a pre-arranged trading plan. The earnings beat highlights stronger-than-anticipated demand for NetScout’s network visibility and cybersecurity offerings, sharpening investor focus on how its AI-enabled solutions and enterprise exposure are shaping the company’s long-term...

If you have been wondering whether Intel is still a bargain after its huge rebound, you are not alone. This article is going to unpack exactly what the current price is really offering. After a rocky few years, Intel's share price has surged, up 82.1% year to date and 88.6% over the last year, even though it pulled back about 2.6% over the past week. Part of this renewed interest comes from Intel pushing aggressively into foundry services to compete with TSMC and seeking major government...

In recent days, TikTok’s parent ByteDance agreed to form a U.S.-based joint venture with Oracle, Silver Lake, and MGX, under which Oracle will oversee TikTok’s U.S. data protection, content moderation, and algorithm security while hosting the platform on its cloud infrastructure. This agreement not only expands Oracle’s cloud workload with a high-traffic consumer app, it also elevates the company’s role in U.S. digital governance and national security-sensitive data oversight. We’ll now...

Zions Bancorporation recently delivered a strong Q3, with revenue rising 9.3% year on year and both revenue and EPS exceeding analyst expectations, benefiting from higher interest rates and ongoing digital banking investments. The results highlight how Zions’ mix of technology upgrades and regional lending strength is helping it stand out among regional banks facing fintech competition and credit risks. We’ll now examine how this earnings beat, alongside improving digital capabilities, may...

Braze (BRZE) has had a busy stretch, with revenue beating expectations, guidance nudged higher, and fresh Buy coverage from BTIG all landing within days. Naturally, investors are asking what comes next. See our latest analysis for Braze. Those upbeat results and new coverage have lit a fire under sentiment, with the 30 day share price return of 30.31 percent standing out against a still negative year to date share price performance. This suggests momentum is rebuilding after a choppy stretch...

Kymera Therapeutics (KYMR) just gave investors a one two punch of good news, with upbeat Phase 1b data for its oral STAT6 degrader KT-621 in atopic dermatitis and an FDA Fast Track designation. See our latest analysis for Kymera Therapeutics. The latest Fast Track nod and strong KT-621 data help explain why Kymera’s 30 day share price return is 29.57% and year to date share price return is 105.40%. This reinforces an already powerful 3 year total shareholder return of 217.18% and suggests...

Earlier this month, Digital Realty Trust announced that Stephen R. Bolze, a veteran infrastructure and industrial executive with leadership experience at Blackstone and General Electric, was elected as an independent director effective January 1, 2026, and will join the Audit Committee. His deep background in power and large-scale infrastructure could be especially important for a data center operator increasingly focused on energy-hungry AI workloads and capacity expansion. Next, we’ll...

Earlier in 2025, American Tower Corporation reported strong Q3 results, with revenue and net income beating expectations helped by favorable foreign currency movements. The company is sharpening its focus on developed markets while rapidly expanding its CoreSite data center platform to capture rising AI-related demand. Next, we’ll examine how this renewed emphasis on CoreSite’s AI-driven data center growth could reshape American Tower’s investment narrative. Explore 28 top quantum computing...